Literature DB >> 20816583

Treatment of Helicobacter pylori infection: the past and the future.

Javier P Gisbert1, José María Pajares.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20816583     DOI： 10.1016/j.ejim.2010.07.009

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN： 0953-6205            Impact factor:   4.487


× No keyword cloud information.
  12 in total

1.  Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori.

Authors:  Marygorret Obonyo; Li Zhang; Soracha Thamphiwatana; Dissaya Pornpattananangkul; Victoria Fu; Liangfang Zhang
Journal:  Mol Pharm       Date:  2012-08-06       Impact factor: 4.939

2.  Update on triple therapy for eradication of Helicobacter pylori: current status of the art.

Authors:  Riccardo Urgesi; Rossella Cianci; Maria Elena Riccioni
Journal:  Clin Exp Gastroenterol       Date:  2012-09-17

3.  A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.

Authors:  P Patrick Basu; Krishna Rayapudi; Tommy Pacana; Niraj James Shah; Nithya Krishnaswamy; Molly Flynn
Journal:  Am J Gastroenterol       Date:  2011-10-11       Impact factor: 10.864

4.  Production of specific IgY Helicobacter pylori recombinant OipA protein and assessment of its inhibitory effects towards attachment of H. pylori to AGS cell line.

Authors:  Katayoun Borhani; Ashraf Mohabati Mobarez; Ali Reza Khabiri; Mehrdad Behmanesh; Nima Khoramabadi
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

5.  Anti-Helicobacter pylori activity and Structure-Activity Relationship study of 2-Alkylthio-5-(nitroaryl)-1,3,4-thiadiazole Derivatives.

Authors:  Ali Asadipour; Najmeh Edraki; Maryam Nakhjiri; Azadeh Yahya-Meymandi; Eskandar Alipour; Parastoo Saniee; Farideh Siavoshi; Abbas Shafiee; Alireza Foroumadi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

6.  Design and evaluation of gastroretentive levofloxacin floating mini-tablets-in-capsule system for eradication of Helicobacter pylori.

Authors:  Sally A El-Zahaby; Abeer A Kassem; Amal H El-Kamel
Journal:  Saudi Pharm J       Date:  2014-03-06       Impact factor: 4.330

7.  Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.

Authors:  Jing Su; Xiaoying Zhou; Han Chen; Bo Hao; Weifeng Zhang; Guoxin Zhang
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

8.  Usefulness of a Helicobacter pylori stool antigen test for diagnosing H. pylori infected C57BL/6 mice.

Authors:  Dae-In Moon; Eun-Hye Shin; Hong-Geun Oh; Jin-Sik Oh; Sunhwa Hong; Yungho Chung; Okjin Kim
Journal:  Lab Anim Res       Date:  2013-03-25

9.  Synthesis and biological evaluation of novel benzyl piperazine derivatives of 5-(5-nitroaryl)-1,3,4-thiadiazoles as Anti-Helicobacter pylori agents.

Authors:  Negar Mohammadhosseini; Parastoo Saniee; Ameneh Ghamaripour; Hassan Aryapour; Farzaneh Afshar; Najmeh Edraki; Farideh Siavoshi; Alireza Foroumadi; Abbas Shafiee
Journal:  Daru       Date:  2013-08-08       Impact factor: 3.117

10.  Effect of Native Gastric Mucus on in vivo Hybridization Therapies Directed at Helicobacter pylori.

Authors:  Rita S Santos; George R Dakwar; Ranhua Xiong; Katrien Forier; Katrien Remaut; Stephan Stremersch; Nuno Guimarães; Sílvia Fontenete; Jesper Wengel; Marina Leite; Céu Figueiredo; Stefaan C De Smedt; Kevin Braeckmans; Nuno F Azevedo
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-08       Impact factor: 10.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.